Skip to content

Get help now

Call or Text 988

New Schizophrenia Treatment Option

A new treatment option has now been approved by the U.S. Food and Drug Administration. The three-month injectable, Invega Trinza, is an atypical antipsychotic used to treat schizophrenia.

Until now, similar drugs administered lasted only about one month. With the option of a long-term injectable, healthcare providers can give patients greater independence by enabling them to focus less on taking their medication and more on other aspects of their treatment plan.

Allowing a longer time between doses can also help healthcare professionals focus on long-term goals with the patient. “With a dosing interval that can be measured in seasons, not days, people living with schizophrenia and their treatment teams can focus on recovery goals beyond short-term symptom control,” said trial investigator Joseph Kwentus, MD, Precise Research Centers.

While this treatment may not be right for everyone, it is great to see new advances in mental health treatment.



About Jill Sauser, The Kim Foundation Project Coordinator
Jill graduated with a degree in Journalism and a minor in Speech Communication from the University of Nebraska at Omaha in 2009. During her time at UNO, she completed a two year PR practicum program where she worked with numerous nonprofit clients including the MS Society, The Archdiocese of Omaha, The Omaha Food Bank, and YWCA. Since becoming Project Coordinator at The Kim Foundation in April 2014, she has become an active member of the Nebraska State Suicide Prevention Coalition, The Omaha Metro Hoarding Taskforce, the Early Childhood Mental Health Coalition, the Metro Area LOSS Team, and is helping lead a community-wide health improvement initiative with the Douglas County Health Department called, “Just Reach Out,” which is focused on improving the people’s view on mental and behavioral health treatment.